BRPI0513551A - uso de equivalentes de aspartato e pelo menos um de vitamina b12 e biotina, e, composição nutricional enteral - Google Patents

uso de equivalentes de aspartato e pelo menos um de vitamina b12 e biotina, e, composição nutricional enteral

Info

Publication number
BRPI0513551A
BRPI0513551A BRPI0513551-6A BRPI0513551A BRPI0513551A BR PI0513551 A BRPI0513551 A BR PI0513551A BR PI0513551 A BRPI0513551 A BR PI0513551A BR PI0513551 A BRPI0513551 A BR PI0513551A
Authority
BR
Brazil
Prior art keywords
equivalents
lactate
ketone
vitamin
biotin
Prior art date
Application number
BRPI0513551-6A
Other languages
English (en)
Inventor
Robert Johan Joseph Hageman
Original Assignee
Nutricia Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35714682&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0513551(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nutricia Nv filed Critical Nutricia Nv
Publication of BRPI0513551A publication Critical patent/BRPI0513551A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
    • A23L13/40—Meat products; Meat meal; Preparation or treatment thereof containing additives
    • A23L13/42—Additives other than enzymes or microorganisms in meat products or meat meals
    • A23L13/424—Addition of non-meat animal protein material, e.g. blood, egg, dairy products, fish; Proteins from microorganisms, yeasts or fungi
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
    • A23L13/60—Comminuted or emulsified meat products, e.g. sausages; Reformed meat from comminuted meat product
    • A23L13/65—Sausages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L23/00—Soups; Sauces; Preparation or treatment thereof
    • A23L23/10—Soup concentrates, e.g. powders or cakes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/185—Vegetable proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pediatric Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)

Abstract

USO DE EQUIVALENTES DE ASPARTATO E PELO MENOS UM DE VITAMINA B12 E BIOTINA, E, COMPOSIçãO NUTRICIONAL ENTERAL Foi verificado que quantidades altas de equivalentes de aspartato em combinação com vitamina B12 e/ou biotina, especialmente na ausência relativa de equivalentes de glutamato, melhoram o metabolismo de corpos de cetona e/ou lactato em um corpo de mamífero, especialmente em condições de doença ou traumáticas. Como um resultado, níveis de níveis de corpos de cetona e lactato podem ser diminuídos e a acidez não fisiologicamente alta normalizada. Assim, é um objetivo da invenção fornecer uma composição nutricional enteral ou farmacêutica para o tratamento e/ou prevenção do metabolismo de cetona e lactato perturbado, isto e, concentrações elevadas de corpos de cetona, lactato e/ou outros ácidos orgânicos e/ou homeostase em pH insuficiente, especialmente concentrações elevadas de corpos de cetona e/ou lactato, em um sangue de mamífero, em que a composição compreende quantidades altas de equivalentes de aspartato em combinação com vitamina B 12 e/ou biotina, preferivelmente na ausência relativa de equivalentes de glutamato.
BRPI0513551-6A 2004-07-19 2005-07-18 uso de equivalentes de aspartato e pelo menos um de vitamina b12 e biotina, e, composição nutricional enteral BRPI0513551A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US58879304P 2004-07-19 2004-07-19
EP04077100 2004-07-19
EP04077359 2004-08-20
PCT/NL2005/000520 WO2006009438A2 (en) 2004-07-19 2005-07-18 Preparation for use of aspartate and vitamin b12 or biotin for regulating ketone bodies

Publications (1)

Publication Number Publication Date
BRPI0513551A true BRPI0513551A (pt) 2008-05-06

Family

ID=35714682

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0513500-1 BRPI0513500C8 (pt) 2004-07-19 2005-07-18 Uso de equivalentes de aspartato e composição nutricional ou farmacêutica
BRPI0513551-6A BRPI0513551A (pt) 2004-07-19 2005-07-18 uso de equivalentes de aspartato e pelo menos um de vitamina b12 e biotina, e, composição nutricional enteral

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0513500-1 BRPI0513500C8 (pt) 2004-07-19 2005-07-18 Uso de equivalentes de aspartato e composição nutricional ou farmacêutica

Country Status (13)

Country Link
US (5) US8003600B2 (pt)
EP (3) EP1771191B1 (pt)
JP (2) JP2008506771A (pt)
CN (3) CN103734746B (pt)
BR (2) BRPI0513500C8 (pt)
CA (2) CA2574360A1 (pt)
DK (2) DK2705849T3 (pt)
ES (3) ES2700463T3 (pt)
NZ (1) NZ552706A (pt)
PL (3) PL1771191T3 (pt)
RU (1) RU2633071C2 (pt)
TR (1) TR201809368T4 (pt)
WO (2) WO2006009438A2 (pt)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1771191T3 (pl) * 2004-07-19 2014-08-29 Nutricia Nv Preparat do zastosowania asparaginianu i witaminy B12 lub biotyny do regulowania poziomu ciał ketonowych
TW200616546A (en) * 2004-09-29 2006-06-01 Asama Kasei Kk A function composition or food containing a whey protein, an antibody from milk or an antibody
EP1853246A1 (en) * 2005-02-17 2007-11-14 Instituto del Metabolismo Celular, S.L. L-aspartic acid for the treatment of problems in connection with the fat or glucose metabolism
EP1774973A1 (en) * 2005-10-12 2007-04-18 Nutricia N.V. Leucine rich composition
WO2008054192A1 (en) * 2006-11-02 2008-05-08 N.V. Nutricia Use of nutritional compositions for preventing disorders
ATE509624T1 (de) * 2005-12-23 2011-06-15 Nutricia Nv Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz
BRPI0620465A2 (pt) * 2005-12-23 2011-11-16 Nutricia Nv uso de uma composição
JP5118125B2 (ja) * 2006-03-23 2013-01-16 ネステク ソシエテ アノニム 高カロリーの栄養補助食品
CA2665164A1 (en) * 2006-10-06 2008-05-15 Nestec S.A. Compositions and multiplex assays for measuring biological mediators of physiological health
WO2008054193A1 (en) 2006-11-02 2008-05-08 N.V. Nutricia Nutritional products that comprise saccharide oligomers
DK2044853T3 (da) 2007-10-02 2011-06-14 Isme Privates Forschungsinstitut Fuer Sport Medizin Und Ernaehrung Gmbh Næringsstof til anvendelse til accelereret fysiologisk præstationsforbedring
US8651126B2 (en) 2007-11-21 2014-02-18 Teva Pharmaceutical Industries, Ltd. Controllable and cleanable steam trap apparatus
WO2010002242A1 (en) 2008-07-02 2010-01-07 N.V. Nutricia Nutritional composition for improving muscle function and daily activity
CA2676518A1 (en) * 2008-08-29 2010-02-28 Kraft Foods Global Brands Llc Whey protein pre-load
WO2010033425A2 (en) * 2008-09-19 2010-03-25 Nestec S.A. Nutritional support to prevent or moderate bone marrow paralysis or neutropenia during anti-cancer treatment
WO2010104374A1 (en) * 2009-03-09 2010-09-16 N.V. Nutricia Nutritional composition inducing a postprandial endocrine response
WO2010112060A1 (en) * 2009-03-30 2010-10-07 Isme Privates Forschungsinstitut Für Sport, Medizin Und Ernährung Gmbh Nutriment for use for accelerated physiological perfomance enhancement
CN102368913A (zh) 2009-04-01 2012-03-07 雀巢产品技术援助有限公司 降低肥胖的风险
US8703719B1 (en) * 2009-05-18 2014-04-22 Bio-Engineered Supplements And Nutrition, Inc. Method and composition for improved muscle performance
WO2011021926A1 (en) * 2009-08-21 2011-02-24 N.V. Nutricia Regulating the amino acid pool used for the acute-phase protein synthesis
WO2012074375A1 (en) * 2010-12-01 2012-06-07 N.V. Nutricia Prevention or treatment of overweight and obesity in type 2 diabetic patients
PH12013501773A1 (en) * 2011-03-31 2013-10-14 Nestec Sa Nutritional compositions for increasing arginine levels and methods of using same
US20140107193A1 (en) * 2011-10-14 2014-04-17 Mead Johnson Nutrition Company Nutritional composition containing a neurologic component of kaempferol and/or fisetin and uses thereof
EP2897472A1 (en) * 2012-09-21 2015-07-29 Abbott Laboratories Nutritional compositions including calcium beta-hydroxy-beta-methylbutyrate, protein and low levels of electrolytes
US10668037B2 (en) * 2012-12-06 2020-06-02 Bio Health Solutions, Llc Treatment for chronic kidney disease
US9669010B2 (en) * 2012-12-06 2017-06-06 Bio Health Solutions, Llc Treatment for chronic kidney disease
US20160000128A1 (en) * 2013-02-15 2016-01-07 Nestec S.A. Food composition and its use
KR102633597B1 (ko) 2013-06-05 2024-02-06 트리시다, 인크. 경구 투여를 위한 양성자-결합 중합체
US9226914B2 (en) * 2013-07-16 2016-01-05 Mead Johnson Nutrition Company Methods for promoting neuronal development and/or health
US9241923B2 (en) * 2013-07-16 2016-01-26 Mead Johnson Nutrition Company Methods for promoting neuronal development and/or health
US20150119322A1 (en) * 2013-07-31 2015-04-30 Mead Johnson Nutrition Company Nutritional compositions containing a prebiotic and lactoferrin and uses thereof
US10709770B2 (en) * 2013-07-31 2020-07-14 Mead Johnson Nutrition Company Nutritional compositions containing a prebiotic and lactoferrin and uses thereof
US9609888B2 (en) * 2013-07-31 2017-04-04 Mead Johnson Nutrition Company Nutritional compositions containing synergistic combination and uses thereof
US20150164833A1 (en) * 2013-12-17 2015-06-18 Mead Johnson Nutrition Company Nutritional composition containing a neurologic component of ursolic acid and uses thereof
IL322207A (en) 2014-12-10 2025-09-01 Tricida Inc Proton-binding polymers for oral administration
WO2016205701A1 (en) 2015-06-19 2016-12-22 University Of Southern California Enteral fast access tract platform system
US10631564B2 (en) 2015-06-19 2020-04-28 University Of Southern California Enterically coated microparticle compositions and methods for modified nutrient delivery
IL262660B2 (en) 2016-05-06 2024-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
RU2644355C1 (ru) * 2017-04-17 2018-02-09 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Соединения на основе пиридоксина, обладающие способностью активировать фермент глюкокиназу
WO2019036471A1 (en) 2017-08-14 2019-02-21 Axcella Health Inc. AMINO ACIDS BRANCHED FOR THE TREATMENT OF LIVER DISEASE
US11255838B2 (en) 2017-11-03 2022-02-22 Lysulin, Inc. Levels, functions, and resistances related to chronic conditions by using lysine-based supplements
US10610544B2 (en) 2017-11-03 2020-04-07 Lysulin, Inc. Insulin resistance and beta cell function using lysine-based supplements
US10656166B2 (en) 2017-11-03 2020-05-19 Lysulin, Inc. Inhibiting chronic blood and nephrological disorders using lysine-based supplements
US10653720B2 (en) 2017-11-03 2020-05-19 Lysulin, Inc. Prevention of protein glycation using lysine/zinc supplements
IL319146A (en) 2017-11-03 2025-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
US11197917B2 (en) 2017-12-01 2021-12-14 ByHeart, Inc. Formulations for nutritional support in subjects in need thereof
EP3810123A1 (en) 2018-06-20 2021-04-28 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
CN110655567B (zh) * 2019-11-12 2021-07-09 云南大学 食品蛋白的磷酸化方法及其磷酸化蛋白
AU2020397933A1 (en) * 2019-12-05 2022-06-30 Flagship Pioneering Innovations V, Inc. Acylated active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
KR20250091590A (ko) * 2023-12-14 2025-06-23 의료법인 성광의료재단 아스파르트산을 포함하는 말초동맥질환의 예방 또는 치료용 약학적 조성물
WO2025235457A1 (en) 2024-05-09 2025-11-13 Alsteni Medical, Inc. Intraoral gastrointestinal access device and related methods

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1560000A (en) 1924-08-15 1925-11-03 Beatrice Sanville Garment button
US4138498A (en) 1976-12-07 1979-02-06 W. R. Grace & Co. Ruminant feed additive
US5116819A (en) 1989-05-05 1992-05-26 Clintec Nutrition Co. Enteral diet for patients with pulmonary disease
FR2657013B1 (fr) 1990-01-18 1992-05-15 Medgenix Group Sa Composition dietetique a base de polypeptides et acides amines.
US5292773A (en) 1990-02-14 1994-03-08 Hirsch Gerald P Treating aids and HIV infection with methionine
US5356873A (en) * 1992-11-05 1994-10-18 Clintec Nutrition Co. Method for providing nutritional requirements to patients having a chronic inflammation reaction
CA2143420C (en) * 1992-12-23 1999-01-19 Phyllis J. B. Acosta Medical foods for the nutritional support of infant/toddler metabolic diseases
US5470839A (en) 1993-04-22 1995-11-28 Clintec Nutrition Company Enteral diet and method for providing nutrition to a diabetic
GB9312369D0 (en) 1993-06-16 1993-07-28 Sandoz Nutrition Ltd Organic compounds
US5438042B1 (en) * 1993-10-08 1997-08-26 Sandoz Nutrition Ltd Enteral nutritional composition having amino acid profile
AU682894B2 (en) 1993-10-28 1997-10-23 Institut National De La Recherche Agronomique Composition based on amino acids intended for the treatment of sepsis or of an attack bringing about an inflammatory reaction, in animals and man
US5576287A (en) * 1994-04-29 1996-11-19 Wake Forest University Method for treating acute renal disease and failure
GB9409646D0 (en) 1994-05-13 1994-07-06 Scient Hospital Suppl Int Ltd Nutritional formulation
US5550166A (en) * 1995-03-17 1996-08-27 Ostlund; Richard E. Pinitol and derivatives thereof for the treatment of metabolic disorders
JPH0965836A (ja) * 1995-08-31 1997-03-11 Hokuren Federation Of Agricult Coop:The α−グルコシダーゼ阻害剤、それを含む糖組成物、甘味料、食品及び飼料
MY115050A (en) 1995-10-16 2003-03-31 Mead Johnson Nutrition Co Diabetic nutritional product having controlled absorption of carbohydrate
WO1997042834A1 (en) 1996-05-13 1997-11-20 Gist-Brocades B.V. Novel food compositions
DE19632452C1 (de) * 1996-08-12 1998-02-19 Cpc International Inc Würzsauce, Verfahren zu deren Herstellung und deren Verwendung
WO1998008521A1 (de) * 1996-08-26 1998-03-05 Oswald Wiss Vitaminpräparate mit sauerstoffsparender wirkung bei körperlicher leistung
DE19701382A1 (de) 1997-01-16 1998-07-23 Nutricia Nv Kohlenhydratmischung
US6042834A (en) * 1997-01-29 2000-03-28 Baraka; Mohamed Wasif Herbal composition for diabetes and method of treatment
US5922766A (en) 1997-07-02 1999-07-13 Acosta; Phyllis J. B. Palatable elemental medical food
RU2145869C1 (ru) * 1999-04-30 2000-02-27 Орещенко Андрей Владимирович Способ антимутагенного воздействия на организм
CA2274414A1 (en) 1999-06-11 2000-12-11 Universite Laval Dietary fish protein for use in restoring normal insulin function insulin-resistant individuals
US6312755B1 (en) * 1999-07-16 2001-11-06 Ampc Whey treatment process for achieving high concentration of α-lactalbumin
GB9927603D0 (en) * 1999-11-22 2000-01-19 Nestle Sa Use of a milk protein hydrolysate in the treatment of diabetes
GB9929497D0 (en) * 1999-12-14 2000-02-09 Vitaflo Limited Improved amino acid mixtures for the treatment and/or management of certain diseases
ZA200109677B (en) * 2000-09-06 2002-06-25 Technikon Pretoria A nutritional and pharmaceutical composition.
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
US6743770B2 (en) 2001-02-14 2004-06-01 Functional Foods, Inc. Nutritional supplement for the management of stress
CN1193691C (zh) * 2001-02-28 2005-03-23 陈胜利 中老年人养生保健饮料及制备方法
US6720312B2 (en) 2001-03-16 2004-04-13 Heartland Health Solutions, Llc Method for controlling the membrane structure of a starch granule
US20030000391A1 (en) 2001-06-12 2003-01-02 Jay Highman Organic nutritional formula
EP1443946A2 (en) 2001-07-03 2004-08-11 Nutri Pharma ASA Composition comprising soy and use thereof in the prevention and/or treatment of various diseases
US6503530B1 (en) 2001-11-01 2003-01-07 Chunghee Kimberly Kang Method of preventing development of severe metabolic derangement in inborn errors of metabolism
US20030118663A1 (en) * 2001-12-24 2003-06-26 Ching-Ming Chang Method and composition for treating diabetes
US6916796B2 (en) 2002-06-12 2005-07-12 Abbott Laboratories Use of pullulan as a slowly digested carbohydrate
GB0213612D0 (en) * 2002-06-13 2002-07-24 Novartis Nutrition Ag Organic compounds
GB0221184D0 (en) 2002-09-13 2002-10-23 Cerestar Holding Bv Carbohydrate materials in food and drink compositions
US6706697B1 (en) * 2002-09-19 2004-03-16 Jason Pharmaceuticals, Inc. Diabetic nutrition and weight loss drink compositions
EP1571925A1 (en) * 2002-12-20 2005-09-14 Unilever N.V. Blood glucose regulating composition
PL1771191T3 (pl) * 2004-07-19 2014-08-29 Nutricia Nv Preparat do zastosowania asparaginianu i witaminy B12 lub biotyny do regulowania poziomu ciał ketonowych

Also Published As

Publication number Publication date
US20110288016A1 (en) 2011-11-24
PL2705849T3 (pl) 2018-09-28
TR201809368T4 (tr) 2018-07-23
CN101018561A (zh) 2007-08-15
CA2574423A1 (en) 2006-01-26
US8501676B2 (en) 2013-08-06
WO2006009438A3 (en) 2006-09-14
BRPI0513500B8 (pt) 2022-05-24
CN101022821B (zh) 2014-01-29
CA2574360A1 (en) 2006-01-26
BRPI0513500A (pt) 2008-05-06
NZ552706A (en) 2011-01-28
CN103734746A (zh) 2014-04-23
US9539278B2 (en) 2017-01-10
BRPI0513500C8 (pt) 2022-06-14
WO2006009437A2 (en) 2006-01-26
BRPI0513500B1 (pt) 2021-03-09
RU2010140355A (ru) 2012-04-10
EP1771191A2 (en) 2007-04-11
DK2705849T3 (en) 2018-05-22
CN103734746B (zh) 2017-01-11
RU2633071C2 (ru) 2017-10-11
DK1771191T3 (da) 2014-06-10
US9889149B2 (en) 2018-02-13
EP1771192A2 (en) 2007-04-11
US20150038453A1 (en) 2015-02-05
ES2467093T3 (es) 2014-06-11
JP2008506772A (ja) 2008-03-06
US8003600B2 (en) 2011-08-23
US20080032916A1 (en) 2008-02-07
US8865649B2 (en) 2014-10-21
JP2008506771A (ja) 2008-03-06
ES2673195T3 (es) 2018-06-20
PL1771192T3 (pl) 2019-02-28
EP1771192B1 (en) 2018-09-12
PL1771191T3 (pl) 2014-08-29
US20080269117A1 (en) 2008-10-30
US20140161928A1 (en) 2014-06-12
EP2705849B1 (en) 2018-04-04
WO2006009437A3 (en) 2006-04-06
CN101022821A (zh) 2007-08-22
WO2006009438A2 (en) 2006-01-26
EP2705849A3 (en) 2014-10-15
EP1771191B1 (en) 2014-03-12
ES2700463T3 (es) 2019-02-15
EP2705849A2 (en) 2014-03-12

Similar Documents

Publication Publication Date Title
WO2006009438A3 (en) Preparation for use of aspartate and vitamin b12 or biotin for regulating ketone bodies
BRPI0519265A2 (pt) composiÇÕes incluindo ferro
BRPI0514026A (pt) composição contendo estatinas e ácidos graxos Èmega-3
RU2014122168A (ru) Улучшение памяти у пациентов с оценкой 24-26 баллов по краткой шкале оценки психического статуса
BRPI0706676B8 (pt) uso de uma solução aquosa com potencial de oxirredução
BRPI0810179B8 (pt) composições de oligoguluronato e galacturonato e usos dos mesmos
ATE534393T1 (de) Zusammenstellungen zur energiesteigerung in vivo
BR112014032905A2 (pt) métodos de redução do risco de um evento cardiovascular em um sujeito em terapia com estatina
BRPI0518565A2 (pt) composiÇÕes cardiovasculares
BRPI0905369B8 (pt) composição farmacêutica, uso da composição farmacêutica e kit compartimentado
BRPI0519242A2 (pt) uso derivados de 1-aminociclohexano para o tratamento de esclerose méltipla, instabilidade emocional e paralisia pseudobulbar
BRPI0622054B8 (pt) composto e composição farmacêutica
MX338247B (es) Metodo de tratamiento de enfermedad de almacenamiento de glucogeno o polisacaridos.
WO2004050033A3 (en) Method of treating cancers
BRPI0610786B8 (pt) uso de um ou mais oligossacarídeos ácidos e neutros, e cisteína e/ou fonte de cisteína, e, composição alimentícia
BRPI0518433A2 (pt) microorganismo para descontaminar fumonisinas e seu uso, mÉtodo para descontaminar fumonisinas, e aditivo para raÇço, que contÉm o dito microorganismo
BR0112919A (pt) Uso de óleos essenciais para combater infecção do trato gi por organismos semelhantes a helicobacter
BR112022018645A2 (pt) Composições e métodos para tratar ou prevenir doenças inflamatórias, incluindo diabetes mellitus tipo i e tipo ii e doenças da tireoide
BR112016000658A2 (pt) pancreatina de alta atividade, processo para a preparação de pancreatina de aa tendo atividade lipásica específica de pelo menos aproximadamente 120 usp iu/mg e método de tratamento de um paciente sujeito a uma condição patológica associada com a insuficiência enzimática pandreática
GT200600463A (es) Derivados de carbamoilbenzotriazol como inhibidores de lipasas y fosfolipasas
BRPI0704529A2 (pt) mÉtodos e dispositivos para a iluminaÇço percutÂnea
Akimov et al. Correction of destructive changes in connective tissues of different organs during chronic nitrate and fluoride intoxication by nanosized silica oxide
Wurtman Synapse formation in the brain can be enhanced by co-administering three specific nutrients
BRPI0517132A (pt) regime de cladribina para o tratamento da esclerose múltipla
WO2017161402A8 (en) Formulation and method for the prevention and/or treatment of hangover symptoms

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]